The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers

Autor: Hugo M. Horlings, Marleen Kok, Stacey E. P. Joosten, Jonna Frasor, Irida Kastrati, Svitlana D. Brovkovych, Svetlana E. Semina, Luis H. Alejo, Joshua D. Stender, Geoffrey L. Greene, Sabine C. Linn, Wilbert Zwart, Elaine T. Alarid
Rok vydání: 2020
Předmět:
0301 basic medicine
Cancer Research
Epithelial-Mesenchymal Transition
Population
Estrogen receptor
Breast Neoplasms
Article
Mice
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
In vivo
Animals
Humans
Medicine
Gene Regulatory Networks
skin and connective tissue diseases
education
Molecular Biology
education.field_of_study
business.industry
Gene Expression Profiling
Estrogen Receptor alpha
NF-kappa B
NF-κB
medicine.disease
In vitro
Gene Expression Regulation
Neoplastic

Gene expression profiling
Tamoxifen
030104 developmental biology
Oncology
chemistry
Drug Resistance
Neoplasm

030220 oncology & carcinogenesis
MCF-7 Cells
Cancer research
Female
Neoplasm Recurrence
Local

business
Neoplasm Transplantation
hormones
hormone substitutes
and hormone antagonists

Signal Transduction
medicine.drug
Zdroj: Mol Cancer Res
ISSN: 1557-3125
1541-7786
Popis: The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications:Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
Databáze: OpenAIRE